“The Physician’s Desk Reference actually shows indications for using antipsychotics for bipolar disease I and II, neurocognitive symptoms associated with borderline personality disorder, Lewy body neuropsychotic symptoms. We even have Nuplazid, which was approved by the FDA in 2016 specifically for the treatment of Parkinson’s psychosis,” said Melanie Tribe-Scott BSN, vice president of Quality Initiatives at Zimmet Healthcare Services Group.
Being torn between taking patients off needed medications and being penalized for it, or choosing another diagnosis that would be excluded from the quality measure “is kind of where this whole issue is coming from now, partially,” said Alicia Cantinieri, vice president of MDS policy and education for Zimmet.
